SG11201906871XA - Rorgamma modulators and uses thereof - Google Patents
Rorgamma modulators and uses thereofInfo
- Publication number
- SG11201906871XA SG11201906871XA SG11201906871XA SG11201906871XA SG11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA SG 11201906871X A SG11201906871X A SG 11201906871XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- diseases
- rorgamma
- pct
- rue
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000001587 cholestatic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305091 | 2017-01-27 | ||
| EP17178889 | 2017-06-29 | ||
| PCT/EP2018/052163 WO2018138356A1 (en) | 2017-01-27 | 2018-01-29 | Rorgamma modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906871XA true SG11201906871XA (en) | 2019-08-27 |
Family
ID=61017942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906871XA SG11201906871XA (en) | 2017-01-27 | 2018-01-29 | Rorgamma modulators and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11160801B2 (pt) |
| EP (1) | EP3573974B1 (pt) |
| JP (1) | JP7138647B2 (pt) |
| KR (1) | KR20190112009A (pt) |
| CN (1) | CN110177782A (pt) |
| AU (1) | AU2018212618A1 (pt) |
| BR (1) | BR112019015399A2 (pt) |
| CA (1) | CA3050045A1 (pt) |
| IL (1) | IL268150A (pt) |
| MX (1) | MX2019008920A (pt) |
| PH (1) | PH12019501683A1 (pt) |
| SG (1) | SG11201906871XA (pt) |
| WO (1) | WO2018138356A1 (pt) |
| ZA (1) | ZA201905513B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023006193A (es) | 2020-11-26 | 2023-06-09 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. |
| KR20240009486A (ko) | 2021-05-19 | 2024-01-22 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 질소 함유 화합물, 이를 포함하는 접합체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| US10035790B2 (en) * | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
| CA2969164A1 (en) | 2014-12-23 | 2016-06-30 | Genfit | Heterocyclic derivatives as rorgamma modulators |
| WO2017010399A1 (ja) * | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
-
2018
- 2018-01-29 WO PCT/EP2018/052163 patent/WO2018138356A1/en unknown
- 2018-01-29 SG SG11201906871XA patent/SG11201906871XA/en unknown
- 2018-01-29 KR KR1020197024251A patent/KR20190112009A/ko unknown
- 2018-01-29 JP JP2019541139A patent/JP7138647B2/ja active Active
- 2018-01-29 BR BR112019015399-3A patent/BR112019015399A2/pt not_active Application Discontinuation
- 2018-01-29 CN CN201880007080.XA patent/CN110177782A/zh active Pending
- 2018-01-29 AU AU2018212618A patent/AU2018212618A1/en not_active Abandoned
- 2018-01-29 CA CA3050045A patent/CA3050045A1/en not_active Abandoned
- 2018-01-29 MX MX2019008920A patent/MX2019008920A/es unknown
- 2018-01-29 US US16/481,172 patent/US11160801B2/en active Active
- 2018-01-29 EP EP18701056.6A patent/EP3573974B1/en active Active
-
2019
- 2019-07-18 IL IL268150A patent/IL268150A/en unknown
- 2019-07-22 PH PH12019501683A patent/PH12019501683A1/en unknown
- 2019-08-21 ZA ZA2019/05513A patent/ZA201905513B/en unknown
-
2021
- 2021-10-05 US US17/494,458 patent/US11974997B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019501683A1 (en) | 2020-06-15 |
| CA3050045A1 (en) | 2018-08-02 |
| AU2018212618A1 (en) | 2019-08-29 |
| KR20190112009A (ko) | 2019-10-02 |
| JP2020505412A (ja) | 2020-02-20 |
| EP3573974B1 (en) | 2024-09-18 |
| MX2019008920A (es) | 2019-12-09 |
| CN110177782A (zh) | 2019-08-27 |
| IL268150A (en) | 2019-09-26 |
| WO2018138356A1 (en) | 2018-08-02 |
| US20190388414A1 (en) | 2019-12-26 |
| US20220133716A1 (en) | 2022-05-05 |
| US11160801B2 (en) | 2021-11-02 |
| BR112019015399A2 (pt) | 2020-03-31 |
| JP7138647B2 (ja) | 2022-09-16 |
| US11974997B2 (en) | 2024-05-07 |
| EP3573974A1 (en) | 2019-12-04 |
| ZA201905513B (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906803WA (en) | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors |